-
The Corbevax booster shot can be administered to individuals who have take first and second dose of either Covaxin or Covishield
-
The study that was carried out among 250 healthcare workers and was published on December 14 in ‘Vaccines’
-
The Hyderabad-based biopharma company, Biological E Limited, which has recently received approval for its Covid vaccine Corbevax
-
New Delhi: The Central government has approved Biological E’s Corbevax for restricted use in an emergency as a heterologous booster dose, official sources confirmed on Wednesday. On Tuesday, ANI had reported that Corbevax booster for heterologous first has been approved by the Centre. Last month the National Technical Advisory Group on Immunisation (NTAGI) recommended Biological […]
-
Hyderabad: Hyderabad-based vaccine company Biological E Limited (BE) on Saturday announced that its Corbevax Covid-19 vaccine has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose to individuals aged 18 years and above. This can be used after six months of administration of primary vaccination (two doses) of Covaxin […]
-
Hyderabad: Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, has announced reduction in the price of its COVID-19 Vaccine Corbevax from Rs. 840 to Rs.250 a dose inclusive of GST, for Private COVID-19 vaccination centres. For the end user, the price would be Rs 400 a dose, including taxes and administration charges. The […]
-
New Delhi: Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India’s first mRNA COVID vaccine to the regulator Drugs Controller General of India (DCGI) on Friday, said sources. The company has also developed an Omicron-specific vaccine which will be tested on humans for efficacy and immunogenicity. Earlier the DG, Indian Council […]
-
Hyderabad: Hyderabad-based vaccine maker Biological E Limited (BE) has priced its Corbevax, which has got approval for administration to adolescents aged 12 to 14 years, at Rs 800 (excluding GST) per dose for the private market, and Rs 145 per dose for the government, making it the cheapest vaccine in India and also globally, the […]
-
Hyderabad: The State Health Department has completed all arrangements to start administering Covid vaccines to children aged 12-14 from Wednesday in Telangana. A total of 17, 23, 000 beneficiaries have been identified and will be administered with Corbevax, the vaccine manufactured by city-based pharma giant Biological E limited. All children born on March 15, 2010, […]
-
New Delhi: The Covid-19 vaccination for all beneficiaries in the 12-14 age group will begin from Wednesday, National Vaccination Day, at all government Covid vaccination centres. The vaccine to be administered would be Corbevax, manufactured by Biological E. Limited, Hyderabad, said Rajesh Bhushan, Union Health Secretary, in a virtual meeting with all states and UTs […]
-
The data has been submitted by the company to the Subject Expert Committee for beneficiaries between 5-12 years of age, the sources told ANI.
-
Hyderabad: The Corbevax vaccine for Covid-19, which recently received Emergency Use Authorisation (EUA) from Indian drug regulators and is being manufactured by Hyderabad-based pharma giant Biological E Limited, has a direct link to top vaccine researchers of United States, who had created, engineered and technology-transferred the vaccine without any patents or strings attached. Led by […]
-
Hyderabad: Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022 which will enable the city-based company to deliver 300 Million doses as promised to the Centre, BE said on Tuesday. Corbevax , India’s […]
-
New Delhi: Amid the ongoing resurgence of new Covid-19 cases in the country, an expert panel of the Central Drugs Standard Control Organisation has approved two new vaccines and one anti-viral drug for restricted use in emergency situation. The CDSCO has granted the Emergency Use Authorization (EUA) to COVOVAX, developed by the Serum Institute of […]
-
Hyderabad: The city has continued to retain its status as the vaccine capital of the country with yet another top-pharmaceutical company Biological E Limited preparing the ground for the launch of its Covid vaccine ‘Corbevax’ in the next few weeks. The Corbevax has successfully completed its second and third phase of clinical trials and the […]
-
New Delhi: Biological E has received approval for conducting phase II/III human clinical trial of Covid-19 vaccine candidate Corbevax on children above five years and adolescents, Department of Biotechnology (DBT) said on Friday. Corbevax, an RBD protein sub-unit vaccine, has been developed with supported from the Department of Biotechnology and its PSU Biotechnology Industry Research […]
-
Hyderabad vaccine maker to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E’s Covid-19 vaccine candidate Corbevax
-
Drug regulatory authorities keen on fast-tracking approvals of new Covid vaccine candidates